ClinicalTrials.gg
TerminatedNCT03532542Updated Sep 19, 2024Results posted

An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy

A Phase 3 interventional study of Casimersen and Golodirsen in Duchenne Muscular Dystrophy, sponsored by Sarepta Therapeutics, Inc.. Terminated at 50 sites in 13 countries. Open to male participants aged 7 Years to 23 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Sarepta Therapeutics, Inc. · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
The trial was stopped to reduce the clinical trial burden on participants while ensuring continued treatment via a post-trial access program with commercially available casimersen and golodirsen. Study was not terminated due to safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
171
Allocation
Non-randomized
Ages
7 Years to 23 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. — 5 open to participants now, 6 under way, 2 of them phase 3. Muscular Dystrophy, Duchenne · Sarepta Therapeutics, Inc..

Enrollment
3rd of 25
171 · median 24
Started
2018
with 4 others
Phase 3
7 of 27
1 open now
Registered
13th of 27
by date

Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., this one is the 3rd largest by enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2018, is one of 7 in phase 3, and was the 13th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

5 of the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 7 Years to 23 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., or all of them as a file.
02

Study summary

The main objective of this study is to evaluate the safety and tolerability of long-term treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD).

03

Conditions studied

  • Duchenne Muscular Dystrophy

Keywords

  • Duchenne muscular dystrophy
  • Exon Skipping
  • DMD
  • Exon 53
  • Exon 45
  • Duchenne
04

Who can participate

Ages eligible
7 Years to 23 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Completed a clinical trial evaluating casimersen or golodirsen, per protocol.
  • Is between 7 and 23 years of age, inclusive, at enrollment.

Other inclusion/exclusion criteria apply.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
171 participants (actual)

Study arms

  • Experimental
    Casimersen

    Patients amenable to exon 45 skipping who have completed a clinical trial evaluating casimersen will receive open-label casimersen intravenous (IV) infusions, weekly, at 30 mg/kg for up to 144 Weeks.

    Drug: Casimersen

  • Experimental
    Golodirsen

    Patients amenable to exon 53 skipping who have completed a clinical trial evaluating golodirsen will receive open-label golodirsen intravenous (IV) infusions, weekly, at 30 mg/kg for up to 144 Weeks.

    Drug: Golodirsen

Interventions

  • Casimersen solution for IV infusion

    Also known as: SRP-4045, AMONDYS 45

  • Golodirsen solution for IV infusion

    Also known as: SRP-4053, VYONDYS 53

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)

    A treatment-emergent adverse event (TEAE) was any untoward medical occurrence in a clinical study participant that did not necessarily have a causal relationship with the study drug. A TEAE could, therefore, be any unfavorable and unintended symptom, sign, disease, condition, or test abnormality that occurred during or after administration of the study drug, whether or not considered related to the study drug. A TESAE was any TEAE that resulted in any of the following outcomes: death, a life-threatening event, required or prolonged inpatient hospitalization, persistent or significant disability/incapacity, or an important medical event (that is, may have jeopardized the participant and may have required medical or surgical intervention to prevent one of the previously mentioned outcomes). A summary of serious and all other non-serious TEAEs regardless of causality is located in the Reported Adverse Events module.

    Time frame: Up to 33 days after the last infusion of study drug (up to approximately 149 weeks)

07

Results

Posted Sep 19, 2024
Limitations and caveats
This study was terminated before all participants had reached the last protocol-defined end-of-study visit. Study termination resulted in participants either being transitioned to a post-trial access program, to another study, or they declined further treatment.

Participant flow

Participants amenable to exon 53 or exon 45 skipping were enrolled into this study from Study 4045-101 (NCT02530905), Study 4053-101 (NCT02310906), and Study 4045-301 (NCT02500381).

Participant flow — Overall Study
MilestoneGolodirsenCasimersen
Started7497
Received at least 1 dose of study drug7497
Completed2627
Not completed4870
Withdrew: Death10
Withdrew: Study terminated by sponsor4165
Withdrew: Withdrawal by subject65

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Serious Adverse Events (TESAEs)

A treatment-emergent adverse event (TEAE) was any untoward medical occurrence in a clinical study participant that did not necessarily have a causal relationship with the study drug. A TEAE could, therefore, be any unfavorable and unintended symptom, sign, disease, condition, or test abnormality that occurred during or after administration of the study drug, whether or not considered related to the study drug. A TESAE was any TEAE that resulted in any of the following outcomes: death, a life-threatening event, required or prolonged inpatient hospitalization, persistent or significant disability/incapacity, or an important medical event (that is, may have jeopardized the participant and may have required medical or surgical intervention to prevent one of the previously mentioned outcomes). A summary of serious and all other non-serious TEAEs regardless of causality is located in the Reported Adverse Events module.

Time frame:
Up to 33 days after the last infusion of study drug (up to approximately 149 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
ParticipantsGolodirsenCasimersen
Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)1222

Adverse events

Collected over Up to 33 days after the last infusion of study drug (up to approximately 149 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Golodirsen1/74 (1.4%)12/74 (16.2%)63/74 (85.1%)
Casimersen0/97 (0%)22/97 (22.7%)93/97 (95.9%)
Most frequent serious events
Showing 10 of 44
Most frequent serious events
EventGolodirsenCasimersen
Femur fractureInjury, poisoning and procedural complications3/748/97
OsteoporosisMusculoskeletal and connective tissue disorders1/742/97
Traumatic fractureInjury, poisoning and procedural complications1/740/97
CellulitisInfections and infestations1/740/97
GastroenteritisInfections and infestations1/740/97
Gastroenteritis viralInfections and infestations1/740/97
HaematuriaRenal and urinary disorders1/740/97
NephrolithiasisRenal and urinary disorders1/740/97
Renal embolismRenal and urinary disorders1/740/97
ScoliosisMusculoskeletal and connective tissue disorders1/741/97
Most frequent other events
Showing 10 of 43
Most frequent other events
EventGolodirsenCasimersen
NasopharyngitisInfections and infestations26/7421/97
VomitingGastrointestinal disorders22/7415/97
HeadacheNervous system disorders22/7425/97
COVID-19Infections and infestations10/7427/97
FallInjury, poisoning and procedural complications19/7417/97
Back painMusculoskeletal and connective tissue disorders17/7417/97
PyrexiaGeneral disorders13/7422/97
CoughRespiratory, thoracic and mediastinal disorders12/7419/97
DiarrhoeaGastrointestinal disorders13/7411/97
Upper respiratory tract infectionInfections and infestations7/7415/97

Baseline characteristics

Safety Analysis Set: All enrolled participants who received at least 1 dose of study drug (golodirsen or casimersen).

Age, Continuous
Age, Continuous(years)GolodirsenCasimersenTotal
Mean11.7 ± 2.1412.2 ± 2.5712.0 ± 2.40
Sex: Female, Male
Sex: Female, Male(Participants)GolodirsenCasimersenTotal
Female000
Male7497171
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)GolodirsenCasimersenTotal
Hispanic or Latino10616
Not Hispanic or Latino5489143
Unknown or Not Reported10212
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)GolodirsenCasimersenTotal
White6586151
Black101
Asian4711
American Indian or Alaska Native101
Native Hawaiian or Other Pacific Islander011
Other336
08

Study locations

50 sites
  • Neuromuscular Research Center
    Phoenix, Arizona 85028, United States
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
  • University of California Los Angeles
    Los Angeles, California 90095, United States
  • Stanford Neuroscience Health Center
    Palo Alto, California 94304, United States
  • Rady Children's Hospital- San Diego
    San Diego, California 92123, United States
  • UF Health: University of Florida Clinical Research Center
    Gainesville, Florida 32610, United States
  • NW Florida Clinical Research Group, LLC
    Gulf Breeze, Florida 32561, United States
  • Rare Disease Research, LLC
    Atlanta, Georgia 30318, United States
  • Ann and Robert H Lurie Childrens Hospital of Chicago
    Chicago, Illinois 60611, United States
  • University of Iowa Childrens Hospital
    Iowa City, Iowa 52242, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Kennedy Krieger Institute
    Baltimore, Maryland 21205, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • St. Louis Children's Hospital
    Saint Louis, Missouri 63110, United States
  • Las Vegas Clinic
    Las Vegas, Nevada 89145, United States
  • University of Rochester Medical Center - Department of Neurology
    Rochester, New York 14642, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Abigail Wexner Research Institute at Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • Shriners Hospital for Children
    Portland, Oregon 97239, United States
  • Children's Hospital of Pittsburgh of UPMC
    Pittsburgh, Pennsylvania 15224, United States
  • Children's Medical Center Dallas
    Dallas, Texas 75207, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
  • University of Utah - PPDS
    Salt Lake City, Utah 84132, United States
  • Children's Hospital of The King's Daughters
    Norfolk, Virginia 23510, United States
  • Children's Hospital of Wisconsin, Corporate Center Suite 540
    Milwaukee, Wisconsin 53226, United States
  • UZ Gent
    Gent, Oost-Vlaanderen 9000, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • University Multiprofile Hospital for active treatment Aleksandrovska EAD Clinic of Neurological Diseases
    Sofia, 1431, Bulgaria
  • Alberta Children's Hospital
    Calgary, Alberta T3B6A8, Canada
  • Children's Hospital of Eastern Ontario
    Ottawa, Ontario K1H 8L1, Canada
  • Fakultni nemocnice Brno, Klinika detske neurologie LF MU a FN Brno
    Brno, 613 00, Czechia
  • Fakultni nemocnice v Motole
    Praha 5, 150 06, Czechia
  • Hotel Dieu- CHU Nantes
    Nantes Cedex, 44093, France
  • Hôpital Armand Trousseau
    Paris, 75013, France
  • Universitatsklinikum Freiberg
    Freiburg, Baden-Wurttemberg 70106, Germany
  • Universitatsklinikum Essen
    Essen, Nordrhein-Westfalen 45147, Germany
  • Schneider Children's Medical Center of Israel
    Petach Tikva, 4920235, Israel
  • UOSD Centro Traslazionale di Miologia e Patologie Neurogenerative
    Genova, Liguria 16147, Italy
  • Azienda Ospedaliero-Universitaria di Ferrara - Arcispedale Sant' Anna
    Cona, 44124, Italy
  • Fondazione Policlinico Universitario A Gemelli
    Milano, 20123, Italy
  • Samodzielny Publiczny Centralny Szpital Kliniczny
    Warsaw, Mazowieckie 02-097, Poland
  • Uniwersyteckie Centrum Kliniczne, Klinica Neurologii Rozwojowej
    Gdansk, 80-952, Poland
  • Hospital de La Santa Creu i Sant Pau
    Barcelona, Cataluña 08041, Spain
  • Hospital Sant Joan de Deu
    Barcelona, 8950, Spain
  • Hospital Universitari i Politecnic La Fe de Valencia
    Valencia, 46026, Spain
  • Provningsenhet Barn, Drottning Silvias Och Ungdomssjukhus
    Goteborg, 41685, Sweden
  • Leeds General Infirmary, Leeds Teaching Hospitals NHS Trust
    Leeds, LS1 3EX, United Kingdom
  • Alder Hey Children's NHS Foundation Trust
    Liverpool, L12 2AP, United Kingdom
  • Great Ormond Street Hospital (GOSH)
    London, WC1N 1EH, United Kingdom
  • Royal Victoria Infirmary
    Newcastle Upon Tyne, NE1 4LP, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in Jul 2023, 59 months.

Results were first posted in Sep 2024, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2018
First posted
May 22, 2018
StartActual
Aug 2, 2018
Primary completionActual
Jul 26, 2023
CompletionActual
Jul 26, 2023
Results first posted
Sep 19, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03532542
Responsible party
Sponsor
First posted
May 22, 2018
Start date
Aug 2, 2018
Primary completion
Jul 26, 2023
Completion
Jul 26, 2023
Results posted
Sep 19, 2024
Last update
Sep 19, 2024

Study contacts

Medical Director
study director · Sarepta Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Casimersen · Golodirsen

Start the discussion